TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23331053

Group type: EXPERIMENTAL
Intervention: Oxybuprocaine hydrochloride (oxybuprocaine HCl)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thera tears (carboxymethylcellulose sodium)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21312329

Group type: EXPERIMENTAL
Intervention: Virtual Collaborative
Number of subjects: 60

Group type: COMPARATOR
Intervention: Toolkit
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 19124223

Group type: EXPERIMENTAL
Intervention: Nurse‐assisted symptom management (NASM)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Automated telephone symptom management (ATSM)
Number of subjects: 354
Study: 17407625

Group type: EXPERIMENTAL
Intervention: Bisacodyl (5-10 mg daily)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Sodium picosulphate (5-10 mg daily)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 144

Group type: COMPARATOR
Intervention: Bisacodyl
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sodium picosulphate
Number of subjects: 144
Study: 14627358

Group type: EXPERIMENTAL
Intervention: Yogurt supplement (227 grams of commercial yogurt for 8 days)
Number of subjects: 202

Group type: COMPARATOR
Intervention: No yogurt supplement
Number of subjects: 202
Study: 10862849

Group type: EXPERIMENTAL
Intervention: Endocervical brushing
Number of subjects: 315

Group type: COMPARATOR
Intervention: Endocervical curettage (ECC)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 315
Study: 9202587

Group type: EXPERIMENTAL
Intervention: Gradient-echo high spatial resolution sequence with split acquisition open mouth views
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spin-echo sequences
Number of subjects: 0
Study: 1527431

Group type: EXPERIMENTAL
Intervention: Cefixime (single oral 400-mg dose)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Ceftriaxone (single intramuscular 250-mg dose)
Number of subjects: 236
Study: 2860181

Group type: COMPARATOR
Intervention: Saline lavage
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Chlorhexidine‐gluconate lavage
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Saline lavage with instillation of povidone‐iodine
Number of subjects: 53
Study: 30734043

Group type: EXPERIMENTAL
Intervention: 15 mg of pioglitazone (titrated to 45 mg daily)
Number of subjects: 2885

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2885
Study: 27624791

Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 154

Group type: COMPARATOR
Intervention: RTX
Number of subjects: 154
Study: 26364029

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrates, activated prothrombin complex concentrates, or recombinant activated factor VII
Number of subjects: 2

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 2
Study: 23709257

Group type: EXPERIMENTAL
Intervention: Ovixan (mometasone furoate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elocon (mometasone furoate)
Number of subjects: 0
Study: 20947533

Group type: EXPERIMENTAL
Intervention: Composite score of protein-energy nutritional status (cPENS) based on albumin, BMI, creatinine, and normalized protein nitrogen appearance (nPNA)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Individual parameters of cPENS (albumin and creatinine)
Number of subjects: 560
Study: 19804705

Group type: EXPERIMENTAL
Intervention: Pradaxa®
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1000
Study: 17536076

Group type: COMPARATOR
Intervention: Normoglycemia
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Isolated impaired glucose tolerance (IGT)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Isolated impaired fasting glucose (IFG)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Combined IFG-IGT
Number of subjects: 700
Study: 15291683

Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Haloperidol (20 mg/day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Risperidone and Haloperidol
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Baseline serum IL‐2 or IL‐8 concentrations
Number of subjects: 78
Study: 11437041

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg b.i.d.) with ursodeoxycholic acid (250 mg t.i.d.)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid alone
Number of subjects: 52
Study: 10489084

Group type: EXPERIMENTAL
Intervention: Paradoxical intention included in treatment program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment program without paradoxical intention
Number of subjects: 0
Study: 7886722

Group type: EXPERIMENTAL
Intervention: Doppler detection of microembolic signals by human observers
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Neuronal network for automated embolus detection
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Repeat examinations of the same patient
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Long-term monitoring of microembolic signals
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Short-term intrasubject variability assessment
Number of subjects: 73
Study: 2224290

Group type: EXPERIMENTAL
Intervention: Programmable hearing aid with eight separate settings
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Programmable hearing aid
Number of subjects: 22

Group type: COMPARATOR
Intervention: Personal hearing aids fitted according to NAL recommendations
Number of subjects: 22
Study: 282097

Group type: EXPERIMENTAL
Intervention: Direct intra-arterial blood pressure measurement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Indirect blood pressure measurement (using regular sized adult cuff and thigh cuff)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pseudohypertension (indirect diastolic greater than 100 mmHg, direct diastolic greater than 90 mmHg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Errors in indirect measurement of blood pressure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Direct intra-arterial measurement
Number of subjects: 40
Study: 31293100

Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail (AO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study: 27566854

Group type: EXPERIMENTAL
Intervention: Fresh corneal graft carrier
Number of subjects: 37

Group type: COMPARATOR
Intervention: Frozen corneal graft carrier
Number of subjects: 37
Study: 24846662

Group type: EXPERIMENTAL
Intervention: 150 mM valine (1.5 mmol/kg BW)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 6
Study: 23542532

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21716064

Group type: EXPERIMENTAL
Intervention: Acamprosate treatment for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Acamprosate treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 23
Study: 19734379

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions) plus self-care advice
Number of subjects: 267

Group type: COMPARATOR
Intervention: Self-care advice only
Number of subjects: 267
Study: 16409565

Group type: EXPERIMENTAL
Intervention: Insulin glargine injection at lunch-time
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Insulin glargine injection at dinner-time
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Insulin glargine injection at bed-time
Number of subjects: 23
Study: 12849652

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy with recurrent MI during index hospitalization
Number of subjects: 20101

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention during index hospitalization
Number of subjects: 20101

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 20101
Study: 10512256

Group type: EXPERIMENTAL
Intervention: Cell salvage devices that do not wash salvaged blood in cardiac surgery
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cell salvage devices that wash or do not wash salvaged blood in orthopedic surgery
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cell salvage devices that do not wash salvaged blood in orthopedic surgery
Number of subjects: 27
Study: 8730415

Group type: EXPERIMENTAL
Intervention: High blood-flow (400 ml/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low blood-flow (200 ml/min)
Number of subjects: 10
Study: 2065846

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6313024

Group type: EXPERIMENTAL
Intervention: Prolonged infusion of suxamethonium during halothane-nitrous oxide anaesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prolonged infusion of suxamethonium during fentanyl-nitrous oxide anaesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neostigmine administration after stopping suxamethonium infusion
Number of subjects: 40
Study: 3914838

Group type: COMPARATOR
Intervention: XRT alone
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: XRT + chemotherapy (concomitant 5-FU during XRT and maintenance 5-FU + MeCCNU)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: XRT + chemotherapy
Number of subjects: 129
Study: 31573608

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 28669071

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27622458

Group type: EXPERIMENTAL
Intervention: Parent‐Child Interaction Therapy (PCIT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 81
Study: 25187584

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg daily for fifty days)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 336
Study: 22854605

Group type: EXPERIMENTAL
Intervention: Immediate-release oral diacetylmorphine (DAM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Slow-release oral morphine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 45
Study: 19717246

Group type: EXPERIMENTAL
Intervention: Experimenter-administered cocaine (0, 12.5, 25 and 50mg/70 kg, i.v.)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cocaine self-administration (0, 12.5 and 25mg/70 kg, i.v.)
Number of subjects: 16
Study: 18435954

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with stenting
Number of subjects: 4

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 4
Study: 16932624

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (combined with corticosteroids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (for induction and maintenance of remission)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab (for patients refractory to cyclophosphamide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azathioprine (combined with corticosteroids)
Number of subjects: 0
Study: 14733345

Group type: EXPERIMENTAL
Intervention: Visual aid (Group A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard informed consent process (Group B)
Number of subjects: 38
Study: 10643347

Group type: EXPERIMENTAL
Intervention: Oral high-dose methylprednisolone (500 mg once daily for five days with a 10 days tapering period)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8777648

Group type: EXPERIMENTAL
Intervention: ictal EEG data in lower frequency bands
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ictal EEG data in higher frequency bands
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ictal EEG data in three frequency bands
Number of subjects: 44
Study: 2059131

Group type: EXPERIMENTAL
Intervention: Rocker-soled shoes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo shoe insert
Number of subjects: 0
Study: 6832707

Group type: EXPERIMENTAL
Intervention: Circulating immune complexes detected by C1q binding assay
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Circulating immune complexes detected by Raji cell assay
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Circulating immune complexes detected by both methods
Number of subjects: 24

Group type: COMPARATOR
Intervention: Levels of circulating immune complexes in PSC patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Raji cell binding of sera from patients with extrahepatic biliary obstruction
Number of subjects: 24
Study: 30799328

Group type: EXPERIMENTAL
Intervention: 10-min holistic self-care program including modified Japanese Radio Taiso, gentle arm exercises, central lymphatic drainage, and skin care for 6 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual care from hospitals
Number of subjects: 43
Study: 29808950

Group type: EXPERIMENTAL
Intervention: Non-elastic taping (NET)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham taping (Control)
Number of subjects: 50
Study: 27153945

Group type: EXPERIMENTAL
Intervention: hydrocortisone
Number of subjects: 72

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 72
Study: 24927639

Group type: EXPERIMENTAL
Intervention: GRAZAX® (75,000 SQ-T/2,800 BAU, ALK, Denmark)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GRAZAX®
Number of subjects: 0
Study: 22056165

Group type: EXPERIMENTAL
Intervention: Alternating low pressure air mattress with multi-stage inflation and deflation cycle of the air cells
Number of subjects: 610

Group type: COMPARATOR
Intervention: Alternating low pressure air mattress with standard single-stage inflation and deflation cycle of the air cells
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 610
Study: 20597561

Group type: EXPERIMENTAL
Intervention: Acupressure wristbands applied at the P6 points
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.2 mg/kg intravenously
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg intravenously
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no acupressure, metoclopramide, or ondansetron)
Number of subjects: 200
Study: 18395934

Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 45
Study: 16022759

Group type: EXPERIMENTAL
Intervention: Purified high-dose anthocyanoside oligomer (100 mg tablet comprising 85% anthocyanoside oligomer), administered twice daily for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo, administered twice daily for 4 weeks.
Number of subjects: 60
Study: 12444837

Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (ORT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravenous therapy
Number of subjects: 34
Study: 11525345

Group type: EXPERIMENTAL
Intervention: JD plus skill training (ST)
Number of subjects: 237

Group type: COMPARATOR
Intervention: JD plus mentoring (MEN)
Number of subjects: 237

Group type: COMPARATOR
Intervention: JD (juvenile diversion)
Number of subjects: 237
Study: 8711605

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.1%)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 55
Study: 2058846

Group type: EXPERIMENTAL
Intervention: Naloxone group (group N): 0.4 mg bolus followed by 5 micrograms.kg‐1.h‐1 infusion for 18 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group (group P): normal saline instead of naloxone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Naloxone group (group N)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group (group P)
Number of subjects: 40
Study: 6600826

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 29933343

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET) and Resistance Training (RT) program, 12 months duration, exercise sessions at 6 days per week, aerobic exercises with incremental training time, resistance exercises with a durable resistance band.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group receiving usual out-patient care, n = 117.
Number of subjects: 60
Study: 27825334

Group type: EXPERIMENTAL
Intervention: Danlou tablets
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 24871808

Group type: EXPERIMENTAL
Intervention: Reference mometasone
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Test mometasone
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 23157761

Group type: EXPERIMENTAL
Intervention: Verbal referrals + telephone health coach/navigator
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Verbal referrals + tailored reminder mailed to their home
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Verbal referrals only
Number of subjects: 1200
Study: 20675411

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 100
Study: 17513394

Group type: EXPERIMENTAL
Intervention: 0.5 g avenanthramide-enriched mixture (AEM)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1 g avenanthramide-enriched mixture (AEM)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 360 mL skim milk (placebo)
Number of subjects: 6
Study: 16156111

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS (25 microg) for 23.33 hours
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS (40 microg) for 23.33 hours
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS (40 microg) for 20 hours followed by 68 hours
Number of subjects: 104

Group type: COMPARATOR
Intervention: IV fentanyl (80 microg/h) administered intermittently over 24 hours
Number of subjects: 104
Study: 12117882

Group type: EXPERIMENTAL
Intervention: L‐NMMA
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10548606

Group type: EXPERIMENTAL
Intervention: Gonal-F (150 IU/day)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Puregon (150 IU/day)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Gonal-F (300 IU/day)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Puregon (300 IU/day)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Gonal-F
Number of subjects: 348

Group type: COMPARATOR
Intervention: Puregon
Number of subjects: 348
Study: 7842204

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bilevel Positive Airway Pressure
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 62
Study: 2384768

Group type: EXPERIMENTAL
Intervention: Duo Formula Group (DFG) self-care programme
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 59
Study: 320990

Group type: EXPERIMENTAL
Intervention: NAB 365
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 0
Study: 31472003

Group type: EXPERIMENTAL
Intervention: Preventive strategy (oral calcium + vitamin D supplementation)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Reactive strategy (therapy in hypocalcemia)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Predictive strategy (therapy if iPTH <10 pg/mL)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Total serum calcium (TSCa)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Ionized calcium (ICa)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone (iPTH)
Number of subjects: 169
Study: 28449795

Group type: EXPERIMENTAL
Intervention: Bosentan (target dose 125 mg twice daily)
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1613

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 1613
Study: 24658022

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 55
Study: 24054398

Group type: EXPERIMENTAL
Intervention: Terazosine plus propiverine HCL
Number of subjects: 100

Group type: COMPARATOR
Intervention: Terazosine and placebo
Number of subjects: 100
Study: 20933466

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Combined treatment (radiotherapy plus immediate androgen suppression with goserelin acetate)
Number of subjects: 415
Study: 18355913

Group type: EXPERIMENTAL
Intervention: 40 Gy in 15 fractions of 2.67 Gy over 3 weeks
Number of subjects: 2215

Group type: COMPARATOR
Intervention: 50 Gy in 25 fractions of 2.0 Gy over 5 weeks
Number of subjects: 2215
Study: 17137013

Group type: EXPERIMENTAL
Intervention: Gymnastics once a week
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Gymnastics twice a week
Number of subjects: 386

Group type: COMPARATOR
Intervention: Health educational program
Number of subjects: 386
Study: 12715790

Group type: EXPERIMENTAL
Intervention: Edaravone (30 mg, twice a day for 14 days)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 11073322

Group type: EXPERIMENTAL
Intervention: Triclosan/oil rinse
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control rinse
Number of subjects: 24
Study: 9176190

Group type: EXPERIMENTAL
Intervention: Progesterone administration at 9:30 PM
Number of subjects: 9
Study: 7844498

Group type: EXPERIMENTAL
Intervention: TV stimulus programs with frequent risk-taking
Number of subjects: 50

Group type: COMPARATOR
Intervention: TV stimulus programs with infrequent physical risk-taking
Number of subjects: 50

Group type: COMPARATOR
Intervention: No TV stimuli
Number of subjects: 50
Study: 3058171

Group type: EXPERIMENTAL
Intervention: FUT‐175 (protease inhibitor)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Regional heparinization (RH)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Low dose heparinization (LH)
Number of subjects: 157